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Objectives
A suitable approach to select cancer stem cells (CSC),
the black seed of melanomas would enable their charac-
terization and elimination.
Methods
Cancerous tissues from primary and metastatic lesions
of patients with malignant melanomas (n=150) were
investigated by cell cultures and molecular genetics.
Double labelled cells were sorted by BD FACSAvia Sorter.
Gene expression analysis by Real Time PCR (MYiQTM,
BIO-RAD) and RNA microarray (Agilent) has been
performed (n=48).
Results
90% of the cell cultures grew and cancer initiating cells
could be IF FACS sorted (0,1% - 1 %). Colocalisation of
unique GD3 sialilated glycosphingolipids and antiCD20
binding was proved. Characteristic growth pattern,
spheroid forming, CSC markers (e.g. CD133, Nestin,
ABCB5, CD20 and unique GD3) was observed (Figure 1.
a,b,c,d). We found enhanced gene expression of CXCR4
and other markers correlated to metastatic potential,
clinical outcome and CSC presence. High throughput
gene expression microarray analysis of RNA preparations
of punch biopsies and CSC outgrowth are compared.
Conclusion
Unique GD3 sialilated glycosphingolipids with colocalised
CD20 proved to be selection markers for CSC in meta-
static melanomas. Our strategy paves the way for detection
and characterization of cancer stem cells and provides
material for therapeutic developments to eliminate the
black seeds of melanomas.
1Molecular Immunology and Toxicology, National Institute of Oncology,
Budapest, Hungary
Full list of author information is available at the end of the article
Figure 1
Kotlan et al. Journal for ImmunoTherapy of Cancer 2013, 1(Suppl 1):P160
http://www.immunotherapyofcancer.org/content/1/S1/P160
© 2013 Kotlan et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Acknowledgements
Harry J Lloyd Charitable Trust Melanoma Research Award.
Authors’ details
1Molecular Immunology and Toxicology, National Institute of Oncology,
Budapest, Hungary. 2Oncodermatology, National Institute of Oncology,
Budapest, Hungary. 3Radiological Diagnostics, National Institute of Oncology,
Budapest, Hungary. 4Pathogenetics, National Institute of Oncology, Budapest,
Hungary. 5Oncosurgery, National Institute of Oncology, Budapest, Hungary.
6Surgical and Molecular Tumorpathology, National Institute of Oncology,
Budapest, Hungary. 7Board of Directors, National Institute of Oncology,
Budapest, Hungary. 8Univ Med Pharm, Tirgu Mures, Romania. 9SIDRA Medical
and Research Center, Doha, Qatar.
Published: 7 November 2013
doi:10.1186/2051-1426-1-S1-P160
Cite this article as: Kotlan et al.: New strategy to reveal the black seeds
of melanomas (cancer stem cells) with their vulnerable characteristics
at cellular and molecular levels. Journal for ImmunoTherapy of Cancer
2013 1(Suppl 1):P160.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Kotlan et al. Journal for ImmunoTherapy of Cancer 2013, 1(Suppl 1):P160
http://www.immunotherapyofcancer.org/content/1/S1/P160
Page 2 of 2
